Research Topics
| Renato CozziSummaryCountry: Italy Publications
|
Detail Information
Publications
Octreotide long-acting repeatable for acromegalyRenato Cozzi
Division of Endocrinology, Ospedale Niguarda, Via Canonica 81, I 20154 Milan, Italy
Expert Rev Clin Pharmacol 5:125-43. 2012..Treatment is well tolerated in most patients and can be safely prolonged for many years if required...
Pregnancy in acromegaly: a one-center experienceRenato Cozzi
Division of Endocrinology, Ospedale Niguarda, Milan, Italy
Eur J Endocrinol 155:279-84. 2006..The aim of the study was the retrospective evaluation of pregnancy in acromegalic women attending our center...
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkageRenato Cozzi
Division of Endocrinology, Ospedale Niguarda, Viale Ezio 5, I 20149 Milan, Italy
J Clin Endocrinol Metab 91:1397-403. 2006..Neurosurgery is regarded as the first-line treatment of acromegaly. Because of its low cure rate in macro and invasive adenoma, the role of primary medical treatment is debated...
Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?R Cozzi
Division of Endocrinology, Niguarda Hospital, Milan, Italy
J Endocrinol Invest 27:1040-7. 2004..The concordance between "safe" GH and normalised IGF-I levels during SA was also assessed, according to gender and gonadal status...
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin statusRenato Cozzi
Division of Endocrinology, Ospedale Niguarda, Carlo Besta Institute, Milan, Italy
Clin Endocrinol (Oxf) 61:209-15. 2004..Even though some data were reported about the addition of cabergoline, a long-acting dopamine agonist (DA), to SA in resistant patients, definite data are still lacking...
Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?Renato Cozzi
Division of Endocrinology, Ospedale Niguarda, I 20162 Milan, Italy
J Clin Endocrinol Metab 88:3090-8. 2003....
Estroprogestinic pill normalizes IGF-I levels in acromegalic womenR Cozzi
Division of Endocrinology, Niguarda Hospital, Milan, Italy
J Endocrinol Invest 26:347-52. 2003..This pilot study shows a marked IGF-I lowering effect of pill in acromegalic women, and warrants a prospective randomized study in patients resistant or partially sensitive to other medical treatments...
Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegalyRoberto Attanasio
Endocrinology Unit, Niguarda Hospital, I-20162 Milan, Italy
J Clin Endocrinol Metab 88:5258-65. 2003....
Gamma-knife radiosurgery in acromegaly: a 4-year follow-up studyRoberto Attanasio
Division of Endocrinology, Ospedale Niguarda, Milan, Italy
J Clin Endocrinol Metab 88:3105-12. 2003....
Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10-year follow-up studyCristina L Ronchi
Department of Medical Sciences, University of Milan, Milan Unit of Endocrinology and Diabetology, Fondazione Ospedale Maggiore IRCCS, Milan, Italy
Clin Endocrinol (Oxf) 71:846-52. 2009..The long-term efficacy and safety of stereotactic radiosurgery by gamma knife (GK) still remain unknown. The aim of the study was to investigate the long-term efficacy and tolerability of GK in acromegalic patients...
Raloxifene lowers IGF-I levels in acromegalic womenRoberto Attanasio
Division of Endocrinology, Ospedale Niguarda, Viale Ezio 5, I-20149 Milan, Italy
Eur J Endocrinol 148:443-8. 2003..e. with values lower than 600 microg/l) and normalizes it in many. A prospective randomized study in patients resistant or partially sensitive to other medical treatments is warranted...
Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter studyRoberto Attanasio
Division of Endocrinology, Joined Hospitals of Bergamo, Italy Pituitary Unit, Galeazzi Institute IRCCS, Milan, Italy
Endocr Pract 14:846-55. 2008..To evaluate the safety and effectiveness of lanreotide Autogel on growth hormone and insulinlike growth factor 1 (IGF-1) concentrations and tumor size in patients with acromegaly...
GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotideR Attanasio
Division of Endocrinology, Niguarda Hospital, Milan, Italy
J Endocrinol Invest 24:209-16. 2001....
A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegalyR Cozzi
Division of Endocrinology, Niguarda Hospital, Milan, Italy
Eur J Endocrinol 141:267-71. 1999....
Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegalyR Cozzi
Division of Endocrinology, Niguarda Hospital, Milan, Italy
Pituitary 3:231-8. 2000..Somatostatin analogues are nowadays the milestone in the medical treatment of acromegaly. We evaluated the effects of a new 60 mg longer-acting formulation of lanreotide (LAN60) on GH/IGF-I levels and tumor size...
Failure of radiotherapy in acromegalyR Cozzi
Division of Endocrinology, Niguarda Hospital, Neurological Institute Carlo Besta, Milan, Italy
Eur J Endocrinol 145:717-26. 2001..Recent data has raised skepticism regarding the long-term effectiveness of radiotherapy (RxT) in acromegaly and its role as an ancillary tool to neurosurgery (Tx)...
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegalyAnnamaria Colao
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
J Clin Endocrinol Metab 91:85-92. 2006..Surgery is a cornerstone in the treatment of acromegaly, but its efficacy in large, invasive tumors is scant...
Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in ItalyMassimo Terzolo
Dipartimento de Scienze Cliniche e Biologische, Clinica Medica, Universita di Torino, Italy
J Clin Endocrinol Metab 90:84-90. 2005..Patients who are found to harbor a colonic neoplasia are at risk for recurrence...
